Compare · GKOS vs RMD
GKOS vs RMD
Side-by-side comparison of Glaukos Corporation (GKOS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GKOS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $27.91B, about 3.8x GKOS ($7.30B).
- Over the past year, GKOS is up 25.3% and RMD is down 23.5% - GKOS leads by 48.7 points.
- GKOS has been more active in the news (11 items in the past 4 weeks vs 7 for RMD).
- Both have 25 recent analyst ratings on file.
- Company
- Glaukos Corporation
- ResMed Inc.
- Price
- $124.22+1.26%
- $192.20-0.70%
- Market cap
- $7.30B
- $27.91B
- 1M return
- -8.91%
- -5.75%
- 1Y return
- +25.26%
- -23.47%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 11
- 7
- Recent ratings
- 25
- 25
Glaukos Corporation
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest GKOS
- Glaukos Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Wen Leana was granted 1,878 shares, increasing direct ownership by 10% to 21,617 units (SEC Form 4)
- Director Weisner Aimee S was granted 1,878 shares, increasing direct ownership by 10% to 20,684 units (SEC Form 4)
- Director Torres Denice was granted 1,878 shares, increasing direct ownership by 8% to 24,212 units (SEC Form 4)
- Director Foley Mark J was granted 1,878 shares, increasing direct ownership by 3% to 60,267 units (SEC Form 4)
- Director Hoffmeister David F was granted 1,878 shares, increasing direct ownership by 4% to 49,549 units (SEC Form 4)
- Director Kliman Gilbert H was granted 1,878 shares, increasing direct ownership by 5% to 37,406 units (SEC Form 4)
- Director Stapley Marc was granted 1,878 shares, increasing direct ownership by 5% to 39,327 units (SEC Form 4)
- SEC Form SD filed by Glaukos Corporation
- Director Hoffmeister David F exercised 15,000 shares at a strike of $24.69, increasing direct ownership by 46% to 47,671 units (SEC Form 4)
Latest RMD
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $968,064 worth of ResMed Common Stock (4,991 units at $193.96) as part of a pre-agreed trading plan, increasing direct ownership by 0.01% to 466,256 units (SEC Form 4)
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett